CoChat

Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality?

Open access
Mallat, Ariane, Lotersztajn, Sophie · 2013 · Journal of Hepatology
Cited by 30

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

COMMENTARY ON: Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9448-53. Copyright (2012). Abstract reprinted by permission from the National Academy of Sciences, USA. http://www.ncbi.nlm.nih.gov/pubmed/22566629Abstract: Myofibroblasts produce the fibrous scar in hepatic fibrosis. In the carbon tetrachloride (CCl(4)) model of liver fibrosis, quiescent hepatic stellate cells (HSC) are activated to become myofibroblasts. When the underlying etiological agent is removed, clinical and experimental fibrosis undergoes a remarkable regression with complete disappearance of these myofibroblasts. Although some myofibroblasts apoptose, it is unknown whether other myofibroblasts may revert to an inactive phenotype during regression of fibrosis. We elucidated the fate of HSCs/myofibroblasts during recovery from CCl(4)- and alcohol-induced liver fibrosis using Cre-LoxP-based genetic labeling of myofibroblasts. Here we demonstrate that half of the myofibroblasts escape apoptosis during regression of liver fibrosis, down-regulate fibrogenic genes, and acquire a phenotype similar to, but distinct from, quiescent HSCs in their ability to more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and strongly contribute to liver fibrosis. Inactivation of HSCs was associated with up-regulation of the anti-apoptotic genes Hspa1a/b, which participate in the survival of HSCs in culture and in vivo. AND Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, Pradere JP, Friedman RA, Schwabe RF. Gastroenterology. 2012 Oct;143(4):1073-83.e22. Copyright © 2012. Abstract reprinted by permission from the AGA Institute. http://www.ncbi.nlm.nih.gov/pubmed/22750464Abstract: Background & Aims: Activated hepatic stellate cells (HSCs), the main fibrogenic cell type in the liver, undergo apoptosis after cessation of liver injury, which contributes to resolution of fibrosis. In this study, we investigated whether HSC deactivation constitutes an additional mechanism of liver fibrosis resolution. Methods: HSC activation and deactivation were investigated by single-cell PCR and genetic tracking in transgenic mice that expressed a tamoxifen-inducible CreER under control of the endogenous vimentin promoter (Vimentin-CreER). Results: Single-cell quantitative polymerase chain reaction demonstrated activation of almost the entire HSC population in fibrotic livers, and a gradual decrease of HSC activation during fibrosis resolution, indicating deactivation of HSCs. Vimentin-CreER marked activated HSCs, demonstrated by a 6- to 16-fold induction of a membrane-bound green fluorescent protein (mGFP) Cre-reporter after injection of carbon tetrachloride, in liver and isolated HSCs, and a shift in localization of mGFP-marked HSCs from peri-sinusoidal to fibrotic septa. Tracking of mGFP-positive HSCs revealed the persistence of 40%-45% of mGFP expression in livers and isolated HSCs 30-45 days after carbon tetrachloride was no longer administered, despite normalization of fibrogenesis parameters; these findings confirm reversal of HSC activation. After fibrosis resolution, mGFP expression was observed again in desmin-positive peri-sinusoidal HSCs; no mGFP expression was detected in hepatocytes or cholangiocytes, excluding mesenchymal-epithelial transition. Notably, reverted HSCs remained in a primed state, with higher levels of responsiveness to fibrogenic stimuli. Conclusions: In mice, reversal of HSC activation contributes to termination of fibrogenesis during fibrosis resolution, but results in higher responsiveness of reverted HSCs to recurring fibrogenic stimulation. Activation of hepatic stellate cells (HSC) in response to chronic liver injury is a key step in the pathogenesis of liver fibrosis. The activation process is characterized by a phenotypic switch from a quiescent vitamin A-rich to a myofibroblastic fibrogenic phenotype [[1]Lotersztajn S. Julien B. Teixeira-Clerc F. Grenard P. Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets.Ann Rev Pharmacol Toxicol. 2005; 45: 605-628Crossref PubMed Scopus (284) Google Scholar] (Fig. 1). Fibrosis has long been viewed as an irreversible process, but convincing clinical and experimental studies have demonstrated that fibrosis resolution may occur upon eradication of the liver insult [[2]Ellis E.L. Mann D.A. Clinical evidence for the regression of liver fibrosis.J Hepatol. 2012; 56: 1171-1180Abstract Full Text Full Text PDF PubMed Scopus (340) Google Scholar]. Experimental models of fibrosis recovery consistently reported that elimination of activated HSC by apoptosis [[3]Iredale J. Benyon R. Pickering J. McCullen M. Northrop M. Pawley S. et al.Mechanisms of sponta

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2013.03.031

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 30

Metadata

Authors
Mallat, A., & Lotersztajn, S.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2013-08
Volume
59
Issue
2
Pages
383-386
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2020973322
Cited by
30
References
8
FWCI
1.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.